A growing body of literature reports on the upregulation of CXC motif chemokine receptor 4
(CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for …

Targeted radionuclide theranostics is becoming more and more prominent in clinical
oncology. Currently, most nuclear medicine compounds researched for cancer theranostics …

CXC motif chemokine receptor 4 (CXCR4)–targeted radioligand therapy (RLT) has already
been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell …

In the early 2000s, major clinical trials provided evidence of a favorable outcome from
antibody-mediated radioimmunotherapy for hematologic neoplasms, which then led to Food …

Focal therapy for localized prostate cancer (PC) using high-intensity focused ultrasound
(HIFU) is gaining in popularity as it is noninvasive and associated with fewer side effects …

Purpose To elucidate the influence of CXC motif chemokine receptor 4 (CXCR4)–directed
imaging on staging and proposed oncologic management in patients with digestive system …

CXC-motif chemokine receptor 4 (CXCR4) is a novel predictive biomarker for metastasis
and poor prognosis in individuals with malignancies. CXCL12 is the only cognate ligand of …

Purpose Recent studies investigating a tumor-sink effect in solid tumors reported on
decreasing uptake in normal organs in patients with higher tumor burden. This …

Integrin αvβ6 has been considered as a promising biomarker for lung cancer, and its
expression is often related to poor prognosis. An αvβ6-binding cystine knot peptide R01-MG …

Chemokines and chemokine receptors are indispensable to play a key role in the
development of malignant tumors. As one of the most widely expressed chemokine …